SCHEMBL577732

SCHEMBL577732

CCCCCCCCCCC[N]C

nearest known ligand 0.53

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.53
THRB P10828 1/20 0.53
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
NAAA Q02083 1/20 0.48
ALDH1A1 P00352 3/20 0.47
DNM1 Q05193 6/20 0.40
LMNA P02545 2/20 0.40
HSD17B10 Q99714 1/20 0.40
SLC22A1 O15245 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL302707 1.00 TSHR (0.53) TSHRTHRBMEN1KMT2ANAAA
SCHEMBL303118 1.00
SCHEMBL9219931 1.00 TSHR (0.53) TSHRTHRBMEN1KMT2ANAAA
SCHEMBL577753 1.00 TSHR (0.53) TSHRTHRBMEN1KMT2ANAAA
SCHEMBL2564589 1.00 TSHR (0.53) TSHRTHRBMEN1KMT2ANAAA
SCHEMBL3386412 1.00 TSHR (0.53) TSHRTHRBMEN1KMT2ANAAA
SCHEMBL2565171 1.00 TSHR (0.53) TSHRTHRBMEN1KMT2ANAAA
SCHEMBL304992 1.00 TSHR (0.53) TSHRTHRBMEN1KMT2ANAAA
SCHEMBL59455 1.00
SCHEMBL303552 1.00 TSHR (0.53) TSHRTHRBMEN1KMT2ANAAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4365180-A1 RARE EARTH COMPLEX Tosoh Corporation (JP) 2024-05-08 EP disclosed
CN-117616032-A Rare earth complex 东曹株式会社 2024-02-27 CN disclosed
WO-2023282236-A1 RARE EARTH COMPLEX 東ソー株式会社 2023-01-12 WO disclosed
CN-108602955-B Photocuring method, compound used in photocuring method, and composition 富士胶片和光纯药株式会社 2021-08-06 CN disclosed
CN-107848963-B Acid-resistant alkali-producing agent and/or radical-producing agent, and curable resin composition containing same 富士胶片和光纯药株式会社 2020-11-03 CN disclosed
CN-110678500-A Photo-or thermosetting method and curable resin composition 富士胶片和光纯药株式会社 2020-01-10 CN disclosed
EP-1640361-B9 ASYMMETRIC UREA COMPOUNDS AND PROCESS FOR PRODUCING ASYMMETRIC COMPOUNDS BY ASYMMETRIC CONJUGATE ADDITION REACTION USING THE SAME AS CATALYST SUMITOMO CHEMICAL CO (JP) 2015-11-04 EP disclosed
US-9073823-B2 Compound having hetero ring skeleton, and process for producing optically active compound using the aforementioned compound as asymmetric catalyst KYOTO UNIVERSITY (JP) 2015-07-07 US disclosed
EP-1640361-B1 ASYMMETRIC UREA COMPOUNDS AND PROCESS FOR PRODUCING ASYMMETRIC COMPOUNDS BY ASYMMETRIC CONJUGATE ADDITION REACTION USING THE SAME AS CATALYST SUMITOMO CHEMICAL CO (JP) 2015-05-27 EP disclosed
US-8809567-B2 Method for producing silylenol ethers KYOTO UNIVERSITY (JP) 2014-08-19 US disclosed
US-20120095227-A1 COMPOUND HAVING HETERO RING SKELETON, AND PROCESS FOR PRODUCING OPTICALLY ACTIVE COMPOUND USING THE AFOREMENTIONED COMPOUND AS ASYMMETRIC CATALYST SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-04-19 US disclosed
US-8153385-B2 Target protein and target gene in drug designing and screening method REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD. (JP) 2012-04-10 US disclosed
EP-2418204-A1 COMPOUND HAVING HETERO RING SKELETON, AND PROCESS FOR PRODUCING OPTICALLY ACTIVE COMPOUND USING THE AFOREMENTIONED COMPOUND AS ASYMMETRIC CATALYST Kyoto University (JP) 2012-02-15 EP disclosed
US-20100136524-A1 TARGET PROTEIN AND TARGET GENE IN DRUG DESIGNING AND SCREENING METHOD REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD. (JP) 2010-06-03 US disclosed
US-7655817-B2 Reacting an azo compound and a compound having an electron-withdrawing group attached to a monohydrogenated carbon using a nonmetal, optically active urea or thiourea catalyst to obtain the hydrazine; reducing to the amine; efficiency;stereospecific; drug product having alpha-amino structure KYOTO UNIVERSITY (JP) 2010-02-02 US disclosed
US-7632970-B2 Asymmetric urea compound and process for producing asymmetric compound by asymmetric conjugate addition reaction with the same as catalyst SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-12-15 US disclosed
US-20060194986-A1 Production methods of optically active hydrazine compound and optically active amine compound KYOTO UNIVERSITY SUMITOMO CHEMICAL COMPANY, LIMITED 2006-08-31 US disclosed
US-20060161006-A1 Asymmetric urea compound and process for producing asymmetric compound by asymmetric conjugate addition reaction with the same as catalyst SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-07-20 US disclosed
EP-1640361-A2 ASYMMETRIC UREA COMPOUND AND PROCESS FOR PRODUCING ASYMMETRIC COMPOUND BY ASYMMETRIC CONJUGATE ADDITION REACTION WITH THE SAME AS CATALYST SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-03-29 EP disclosed
US-6352821-B1 DEVELOPING SILVER HALIDE COLOR PHOTOGRAPHIC LIGHT-SENSITIVE MATERIAL, SUPPLYING ACIDIC SOLUTION HAVING PH OF 4 OR LESS, IN FORM OF THIN LAYER, ONTO LIGHT-SENSITIVE MATERIAL, SO AS TO HAVE SPECIFIED COVERAGE FUJI PHOTO FILM CO., LTD. (JP) 2002-03-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100136524-A1 TARGET PROTEIN AND TARGET GENE IN DRUG DESIGNING AND SCREENING METHOD CHP1, CMA1, CARHSP1 TSHR 4022/4885THRB 2985/4885MEN1 4848/4885
US-20120095227-A1 COMPOUND HAVING HETERO RING SKELETON, AND PROCESS FOR PRODUCING OPTICALLY ACTIVE COMPOUND USING THE AFOREMENTIONED COMPOUND AS ASYMMETRIC CATALYST CCNL2, ASH2L, AHR TSHR 2501/4885THRB 1410/4885MEN1 820/4885
US-20060161006-A1 Asymmetric urea compound and process for producing asymmetric compound by asymmetric conjugate addition reaction with the same as catalyst RAD18, UTP18, UBE2G2 TSHR 1711/4885THRB 2798/4885MEN1 2949/4885
US-20060194986-A1 Production methods of optically active hydrazine compound and optically active amine compound H1-0, H1-5, H1-10 TSHR 1660/4885THRB 3588/4885MEN1 3387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.